Fig. 1: Schema of AAV constructs and experimental procedure.

a–e AAV vectors comprise the constitutive PGK promoter (a) or Iba1 promoter (b–e) followed by GFP, WPRE, and polyA. In addition, one or two sets of four repeated microRNA (miR) target sequences (4 × miR-9.T and 4 × miR-129-2-3p.T or 4 × miR-136-5p.T) were inserted between the WPRE and polyA sequences (a, c–e). Each construct was labeled with the abbreviated promoter name (PGK or Iba1) plus incorporated miR target(s) as described. f Mice received different doses of each AAV vector (3.9 × 10¹² vg/mL) to the cerebral cortex (0.5 μL), striatum (1 μL), and cerebellum (10 μL). One week after the viral injection, the brains of the treated mice were examined by immunohistochemistry. GFP enhanced green fluorescent protein, Iba1 ionized calcium-binding adapter molecule 1, IHC immunohistochemistry, ITR inverted terminal repeat, PGK phosphoglycerate kinase 1, polyA simian virus 40 polyadenylation signal sequence, WPRE woodchuck hepatitis virus post-transcriptional regulatory element.